QC
NGNE icon

Quadrature Capital’s Neurogene NGNE Stock Holding History

Quadrature Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765K Buy
+24,320
New +$670K 0.01% 833
2025
Q4 		– Sell
-16,828
Closed -$292K – 1533
2025
Q3 		$292K Buy
+16,828
New +$338K ﹤0.01% 680

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Quadrature Capital's NGNE Position: Q2 2026 in Review

Quadrature Capital opened a new position in Neurogene (NGNE) in Q2 2026: 24,320 shares worth $765K. The stake represents 0.01% of the portfolio and ranks #833 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in NGNE as recently as Q3 2025.

Quadrature Capital first reported a position in NGNE in Q3 2025 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Quadrature Capital held 24,320 shares of Neurogene worth $765K as of Q2 2026.
  • Neurogene was a new Quadrature Capital position in Q2 2026.
  • Neurogene made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #833 holding.
  • Quadrature Capital first reported a position in Neurogene in Q3 2025 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.